Going digital is a huge feat, and something well worth celebrating. But the labs seeing the biggest returns chose a platform that keeps compounding value long after go-live, scaling across departments and teams without friction, opening new revenue streams, and evolving alongside their ambitions.
KLAS Research’s Digital Pathology 2026 report reinforces the importance of a long-term view. Proscia earned a 95.2 out of 100, the highest overall performance score in the US market following our Best in KLAS win in Europe, based solely on customer feedback. And that feedback isn’t about checking the box on the initial deployment. It’s about scalability, continuous improvement, and long-term strategic value.
Here’s a deeper look at what our customers highlighted, why 100% of those surveyed said they’d buy again, and what it takes to turn a digital pathology investment into a lasting competitive advantage.
Hear directly from Eder Lagemann, KLAS’ VP of Engagement, for more on their methodology and Proscia’s top ratings.
A Platform That Keeps Getting Better
The real test of a long-term partner is whether its product actually evolves. Concentriq earned an ‘A’ grade for its strength today and received the highest score for delivery of new technology.
These ratings reflect our commitment to adding value. New releases ship quarterly, shaped by input from a growing network of pathologists, not just a product team in a vacuum.
100% of customers told KLAS that Proscia “keeps all promises.” This is a reflection of our commitment to saying what we’re going to build, building it, and making sure it has an impact.
Scaling Beyond the Pilot — Without Outgrowing Your Platform
“Will this thing actually scale?” is the question that keeps many digital pathology leaders at large organizations up at night. KLAS’ data answers it directly: they validated one of the largest digital pathology deployments within a single organization on Concentriq.
But volume is only half the scalability equation. As your technology ecosystem grows (more scanners, more AI tools, more LIS connections), your platform has to unify that environment, not add to the fragmentation. Concentriq earned top marks for supporting customers’ integration goals, reflecting its bidirectional connections with more than 15 unique LIS and its role as a hub for 130+ AI applications. And through the Proscia Ready partner alliance, these integrations are reinforced by joint support agreements and a shared vision for the future.
A Dedicated Customer Experience Practice Invested In Your Success
One of the best ways to spot a true partner is by how its team shows up after the contract is signed. Our customer experience organization spans professional services, support, and customer success to ensure you’re supported at every stage of the journey—during go-live, whenever issues arise, and as you grow with Concentriq.
KLAS’ data validates the impact that this group provides. Customers awarded Proscia an ‘A+’ for the relationships we form and highlighted the quality of implementation, training, and support. They also pointed to executive involvement as a sign that leadership engagement extends well beyond the sales process.
A Strategic Partner That Unlocks New Revenue Opportunities
Most digital pathology conversations center on experience, efficiency, and quality. Those matter enormously. But the labs getting the most from their investment have moved beyond operational gains and into revenue generation.
Laboratories leveraging Concentriq have already generated millions of dollars in high-margin revenue by unlocking the value of their real-world pathology data. They can also support clinical trial matching, companion diagnostic development, and more through our Proscia Aperture model.
Here’s how: Concentriq is also the platform of choice for life sciences organizations, including 16 of the top 20 pharmaceutical companies. That creates a network that expands a laboratory’s role in drug development and precision medicine programs.
The majority of our customers interviewed told KLAS that Proscia takes a highly strategic approach. This is what they mean: a partner that helps you see digital pathology as a growth engine.
Backed by Trusted Customer Evaluations
KLAS Research has earned its place as the most respected independent analyst firm in healthcare IT, serving as an industry benchmark for nearly 30 years. As Eder Lagemann, KLAS’ VP of Engagement, explains in the video above, the firm has built its reputation on a sustained focus on voice-of-the-customer research and a proven methodology. These aren’t analyst opinions. They’re the aggregated, unfiltered experiences of the people actually using the technology every day.
- View the Digital Pathology 2026 report
- Watch our on-demand webinar “Inside Concentriq” for a look at the top-rated platform
